Acrivon Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Acrivon Therapeutics, Inc. (ACRV), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ACRV insiders buying or selling?
In the last 12 months, Acrivon Therapeutics, Inc. insiders reported 3 open-market purchases ($114.3K) and 9 sales ($40.4K) — net buying of $73.9K. Since November 2022, Trabud has recorded 20 Form 4 filings for ACRV: 6 buys ($67.5M) and 14 sells ($3.9M).
Source: SEC EDGAR Form 4
Key Statistics (November 2022 – Oct 7, 2026)
Total Form 4 filings
20
SEC EDGAR
Insider filers
9
Insider buys (6)
$67.5M
Insider sells (14)
$3.9M
Insider sentiment
Net buyingNet insider flow of $63.6M in net buying since November 2022, and $73.9K in net buying over the last 12 months.
Recent ACRV insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Mary Miller | Chief Legal Officer | Sale | 294 | $1.99 | $585.06 | SEC ↗ |
| Aug 27, 2026 | Peter Blume-Jensen | President and CEO | Sale | 14.0K | $2.21 | $31.0K | SEC ↗ |
| Aug 20, 2026 | Katharine Peterson | Chief Accounting Officer | Sale | 101 | $2.01 | $203.01 | SEC ↗ |
| Aug 20, 2026 | Mary Miller | Chief Legal Officer | Sale | 185 | $2.01 | $371.85 | SEC ↗ |
| Aug 20, 2026 | Erick Gamelin | Chief Development Officer | Sale | 400 | $2.01 | $804 | SEC ↗ |
| Aug 20, 2026 | Eric Devroe | Chief Operating Officer | Sale | 604 | $2.01 | $1.2K | SEC ↗ |
| Aug 20, 2026 | Peter Blume-Jensen | President and CEO | Sale | 1.7K | $2.01 | $3.4K | SEC ↗ |
| Aug 6, 2026 | Adam D. Levy | Chief Financial Officer | Sale | 1.1K | $1.57 | $1.8K | SEC ↗ |
| Jul 23, 2026 | Mary Miller | Chief Legal Officer | Sale | 573 | $1.76 | $1.0K | SEC ↗ |
| Jan 16, 2026 | Peter Blume-Jensen | President and CEO | Purchase | 49.0K | $1.68 | $82.1K | SEC ↗ |
| Jan 16, 2026 | Adam D. Levy | Chief Financial Officer | Purchase | 8.8K | $1.70 | $15.0K | SEC ↗ |
| Jan 15, 2026 | Eric Devroe | Chief Operating Officer | Purchase | 10.0K | $1.72 | $17.2K | SEC ↗ |
| May 1, 2025 | Joseph Edelman | 10% Owner | Sale | 736.8K | $1.38 | $1.0M | SEC ↗ |
| Apr 29, 2025 | Joseph Edelman | 10% Owner | Sale | 1.5M | $1.81 | $2.7M | SEC ↗ |
| Apr 15, 2024 | Joseph Edelman | 10% Owner | Purchase | 2.4M | $8.50 | $20.0M | SEC ↗ |
| Jun 28, 2023 | Marcin Czernik | 10% Owner | Sale | 16 | $12.93 | $206.88 | SEC ↗ |
| Jun 20, 2023 | Marcin Czernik | 10% Owner | Sale | 2.1K | $12.14 | $25.0K | SEC ↗ |
| Jun 14, 2023 | Marcin Czernik | 10% Owner | Sale | 5.9K | $12.29 | $72.4K | SEC ↗ |
| Nov 21, 2022 | Marcin Czernik | 10% Owner | Purchase | 400.0K | $12.50 | $5.0M | SEC ↗ |
| Nov 21, 2022 | Peter Kolchinsky | Director, 10% Owner | Purchase | 3.4M | $12.50 | $42.4M | SEC ↗ |
Showing the 20 most recent of 20 Form 4 filings for Acrivon Therapeutics, Inc..
Most active ACRV insiders
- Marcin Czernik4 filings
- Mary Miller3 filings
- Joseph Edelman3 filings
- Peter Blume-Jensen3 filings
- Adam D. Levy2 filings
Ask anything about ACRV insider activity
Use Trabud's AI agent to query Acrivon Therapeutics, Inc.'s Form 4 history in plain English — "Show me ACRV CEO purchases this year" or compare it against any other ticker.
Open the AI agentACRV insider trading FAQ
Are Acrivon Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Acrivon Therapeutics, Inc. insiders reported 3 open-market purchases ($114.3K) and 9 sales ($40.4K) — net buying of $73.9K. Since November 2022, Trabud has recorded 20 Form 4 filings for ACRV: 6 buys ($67.5M) and 14 sells ($3.9M). Over the full record that is net buying of $63.6M.
How many insiders trade ACRV stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Acrivon Therapeutics, Inc.. The most recent filing was accepted on Oct 7, 2026.
Where does Trabud get ACRV insider trading data?
All ACRV insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.